Exelixis has announced that it will begin the pivotal Phase III ‘306 trial of cabozantinib in patients with metastatic castration-resistant prostate cancer by the end of 2011.

The double-blind ‘306 trial is expected to enrol 246 CRPC patients, who will be randomised 1:1 to receive either cabozantinib or mitoxantrone / prednisone.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The alleviation of bone pain will be the primary endpoint of the study, while secondary endpoints include overall survival rate and bone scan response.

An earlier Phase II trial with cabozantinib demonstrated favourable effects on bone and soft tissue lesions, and in the relief of bone metastasis-related pain in castration-resistant prostate cancer patients.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact